Subtype
Bladder Neoplasm
CI-CAN-00001978Explore in graph →
Non-malignant390 active trials10 approved drugs25 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001978Explore in graph →
Clinical trials
1,701 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06281080 | First-in-Human Trial of a Novel Endoluminal Robotic System for En-Bloc Resection of Bladder Tumours | recruiting | N/A | 10 | Chinese University of Hong KongOTHER | 1 | Feb 6, 2025 | clinicaltrials |
| NCT06775977 | Ultrasound Contrast-Enhanced Accurate Diagnosis of Preoperative Staging of Bladder Cancer(UCEADP-BCS) | recruiting | — | 480 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 |
| Jan 24, 2025 |
| clinicaltrials |
| NCT06780358 | Study of bladdeR Cancer Detection in Standard White Light Versus AI-Supported Endoscopy-02(RAISE02) | enrolling by invitation | N/A | 64 | CystotechINDUSTRY | 1 | Jan 17, 2025 | clinicaltrials |
| NCT04724928 | Evaluating the Impact of 18F-FDG-PET-CT on Risk Stratification and Treatment Adaptation for Patients with Muscle Invasive Bladder Cancer(EFFORT-MIBC) | recruiting | Phase 2 | 156 | University Hospital, GhentOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT06186414 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC | recruiting | Phase 1 | 152 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 15, 2025 | clinicaltrials |
| NCT05204108 | Preoperative Detection of Muscle Invasion in Bladder Cancer with Contrast-enhanced Ultrasonography | recruiting | — | 1,000 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT06732531 | Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer | recruiting | Phase 1 / Phase 2 | 48 | Zhuhai Beihai Biotech Co., LtdINDUSTRY | 1 | Jan 9, 2025 | clinicaltrials |
| NCT06762925 | Study on the Efficacy and Mechanism of METTL3 Peptide Inhibitors in Enhancing Anti-tumor Immune Response by Reshaping the Tumor Microenvironment | not yet recruiting | — | 450 | Xijing HospitalOTHER | 0 | Jan 8, 2025 | clinicaltrials |
| NCT06751667 | Xpert Bladder Monitor: a Non-Invasive Follow-Up Tool for Detecting Relapse in High Grade or High Risk Bladder Cancer(LIBERO) | not yet recruiting | N/A | 50 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 0 | Dec 30, 2024 | clinicaltrials |
| NCT05790850 | Pre-Habilitation with Mindfulness and Exercise for Patients Undergoing Radical Cystectomy (PRIMER Trial)(PRIMER) | recruiting | N/A | 30 | University of VirginiaOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06719232 | Evaluating the Efficacy and Patient Experience of Catheter-Free Intravesical Instillation(NOCATIN) | recruiting | — | 300 | Jahn Ferenc South Pest Teaching HospitalOTHER_GOV | 1 | Dec 12, 2024 | clinicaltrials |
| NCT03799835 | Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients(ALBAN) | active not recruiting | Phase 3 | 517 | UNICANCEROTHER | 3 | Dec 11, 2024 | clinicaltrials |
| NCT04811846 | CTC Quantification During TURBT and PKVBT of Transitional Cell Carcinoma in Purging Fluid and Blood | active not recruiting | N/A | 40 | University Teaching Hospital Hall in TirolOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06679920 | Study With a Newly Optical Coherence Tomography Probe for Optimizing Bladder Cancer Diagnosis and Treatment(BLOCT) | recruiting | N/A | 15 | Amsterdam UMCOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT04289779 | Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer(ABATE) | active not recruiting | Phase 2 | 46 | Deepak KilariOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT04562311 | Chidamide With Immunotherapy for Patients With Locally Advanced or Metastatic Urothelial Carcinoma | active not recruiting | Phase 2 | 45 | Sun Yat-sen UniversityOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT04861584 | Neoadjuvant Toripalimab in Combination with Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects | recruiting | Phase 2 | 41 | Zhujiang HospitalOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT05067101 | Comparison Capsule Sparing Cystectomy and Radical Cystoprostatectomy in Men with Bladder Cancer | recruiting | N/A | 126 | Zhujiang HospitalOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT06341400 | RC48 Combined with Toripalimab As Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients | recruiting | Phase 1 / Phase 2 | 55 | Zhujiang HospitalOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT05453682 | Hypofractionated IMRT With Concurrent Chemotherapy in Muscle-invasive Bladder Cancer (HIRACUM)(HIRACOM) | recruiting | N/A | 53 | Samsung Medical CenterOTHER | 1 | Dec 2, 2024 | clinicaltrials |
| NCT06119724 | Bipolar Enbloc Versus Thulium-Yag Enbloc Resection of Bladder Tumors(TURBT-Enbloc) | active not recruiting | N/A | 50 | Menoufia UniversityOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT06694649 | Better in Better Out Cystectomy.(BIBOCYS-1) | not yet recruiting | — | 100 | Ziekenhuis Oost-LimburgOTHER | 0 | Nov 19, 2024 | clinicaltrials |
| NCT06675656 | Predictive Role of Microbiome in Patients With Urothelial Carcinoma | not yet recruiting | — | 420 | IRCCS San RaffaeleOTHER | 0 | Nov 5, 2024 | clinicaltrials |
| NCT04167631 | Can VI-RADS/ADC Accurately Stage Bladder Cancer?? | active not recruiting | N/A | 150 | Mansoura UniversityOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT05969964 | Can Second Resection for pT1 Bladder Cancer be Avoided After Initial En-Bloc Resection With Negative Safety Margins | recruiting | — | 370 | Mansoura UniversityOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT06662071 | A Research Protocol for Evaluating the Efficacy of Perfused Chemotherapeutic Agents for Bladder Cancer Based on Organoid Technology | recruiting | — | 293 | Qilu Hospital of Shandong UniversityOTHER | 1 | Oct 28, 2024 | clinicaltrials |
| NCT04979156 | LaserEn: SOLTIVE™ Thulium Laser Fiber En Bloc Resection of Bladder Tumors(LaserEn) | recruiting | — | 20 | University of Kansas Medical CenterOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT05215574 | Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 130 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Oct 10, 2024 | clinicaltrials |
| NCT06630871 | A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk. | not yet recruiting | Phase 2 | 40 | Fujian Medical University Union HospitalOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT05203913 | Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer(CNN-BC) | recruiting | Phase 2 | 32 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Oct 4, 2024 | clinicaltrials |
| NCT05878964 | Evaluation of Skin Health and QoL in Pts Receiving Anti-PD1/PDL1/CTLA4 or CDK Inhibitors.(SkinHealth) | recruiting | — | 420 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Oct 4, 2024 | clinicaltrials |
| NCT05153694 | Infectious Complications After Cystectomy: A Prospective Observational Study | recruiting | — | 200 | Ludwig-Maximilians - University of MunichOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06588179 | SHR-1501 Combined With SHR-2005 for High-Risk Non-Muscle Invasive Bladder Cancer Which is Not Completely Resectable by TURBt | not yet recruiting | Phase 1 / Phase 2 | 58 | Fudan UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04498767 | Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)(OligoRARE) | recruiting | N/A | 200 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 7 | Aug 26, 2024 | clinicaltrials |
| NCT06548438 | The Impact of PDD During TURB for NMIBC(TUR_BLUE) | not yet recruiting | Phase 4 | 300 | A.O.U. Città della Salute e della ScienzaOTHER | 0 | Aug 12, 2024 | clinicaltrials |
| NCT06528483 | Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder Cancer(preSAVE) | not yet recruiting | Phase 2 | 63 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT06310369 | Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer | not yet recruiting | Phase 2 | 50 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | Jul 22, 2024 | clinicaltrials |
| NCT06469229 | Performance Evaluation of Urine DNA Methylation Testing for the Detection of Urothelial Carcinoma in Patients With Hematuria | not yet recruiting | — | 1,200 | Changhai HospitalOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT06474338 | AI Detection of Bladder Tumors Under Endoscopy | recruiting | — | 1,000 | Peking Union Medical College HospitalOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05739968 | Impacts and Testing of the "Multi-domains Active-living Program" in Operable Non-Muscle Invasive Bladder Cancer Patients | recruiting | N/A | 120 | National Taiwan University HospitalOTHER | 1 | Jun 5, 2024 | clinicaltrials |
| NCT06441110 | Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer | recruiting | Phase 3 | 76 | Fujian Medical University Union HospitalOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT05397262 | Organ-preservative Therapy of Bladder Cancer With Radiotherapy or Radiochemotherapy Combined With Hyperthermia(HyBla_RCT) | recruiting | N/A | 1,000 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT06357416 | The Man Van Project(MV) | recruiting | N/A | 4,000 | Royal Marsden NHS Foundation TrustOTHER | 1 | May 1, 2024 | clinicaltrials |
| NCT06355518 | Pre-operative Immuno-Nutrition in Radical Cystectomy(INu-RC) | not yet recruiting | N/A | 260 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT06341478 | Investigator Grant (IG) 2022 27746 | recruiting | N/A | 153 | IRCCS San RaffaeleOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT03973671 | Prospective Sample Collection for Cancer of Bladder(ProCaB) | recruiting | — | 300 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Mar 28, 2024 | clinicaltrials |
| NCT06325423 | Predicting Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer | not yet recruiting | — | 50 | Assiut UniversityOTHER | 0 | Mar 26, 2024 | clinicaltrials |
| NCT05200988 | Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC(Indi-Blade) | active not recruiting | Phase 2 | 50 | The Netherlands Cancer InstituteOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT05219734 | MRD Assay Evaluates Recurrence and Response Via a Tumor Informed Assessment(MARIA) | active not recruiting | — | 400 | Invitae CorporationINDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06289283 | Microbiota in Urine and Urothelium Can be a Factor for Induction of Urinary Bladder Cancer. The Study Will Examine Urine and Bladder Cancer Tissues From Male Patients and Urine of Controls Using Whole Genomic Sequencing Techniques and 16S rRNA. The Aim is to Elucidate Role of Microbiota in Bladder(Cancer bladder) | active not recruiting | — | 38 | Theodor Bilharz Research InstituteOTHER | 1 | Mar 1, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Feb 6, 2025source: clinicaltrials